Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: DPP4 inhibitor Clear all
Completed Phase 3 Interventional Results available

The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

NCT01106677
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin, Sitagliptin, Metformin immediate release
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
45
States / cities
Little Rock, Arkansas • Fountain Valley, California • National City, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM

NCT01856907
View directory record Official record
Conditions
Disorder of Glucose Regulation
Interventions
Sitagliptin-Metformin, Metformin, Placebo pill
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 3 Interventional Results available

Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis

NCT02022007
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Disorder of Glucose Regulation
Interventions
Metformin XR, Saxagliptin, Saxagliptin-Metformin XR
Drug
Lead sponsor
Woman's
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Results available

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

NCT03951805
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin Glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Anaheim, California • Lancaster, California • Roswell, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 4 Interventional Results available

Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients

NCT02024477
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
George Washington University
Other
Eligibility
40 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 3 Interventional Results available

The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)

NCT01137812
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Sitagliptin 100 mg, Canagliflozin 300 mg, Metformin, Sulphonylurea
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
85
States / cities
Mobile, Alabama • Goodyear, Arizona • Mesa, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Oct 20, 2026, 3:58 PM EDT
Completed No phase listed Observational Results available

Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy

NCT02140645
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
166,613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 4 Interventional Results available

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

NCT02741687
View directory record Official record
Conditions
Hyperglycemia
Interventions
Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Results available

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

NCT03751657
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Placebo (insulin 287), Metformin, Dipeptidyl peptidase-4 inhibitors, Insulin glargine, Placebo (insulin glargine)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Lancaster, California • Ventura, California • Walnut Creek, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 20, 2026, 3:58 PM EDT
Completed No phase listed Observational

Replication of the EMPAREG Diabetes Trial in Healthcare Claims

NCT04215536
View directory record Official record
Conditions
Diabetes
Interventions
Empagliflozin, DPP-4 inhibitor
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
103,752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 4 Interventional Results available

Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes

NCT01378117
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hospitalization, Hyperglycemia
Interventions
Sitagliptin, glargine, lispro
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 20, 2026, 3:58 PM EDT
Terminated Phase 3 Interventional

Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment

NCT00958269
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Renal Impairment
Interventions
dutogliptin, placebo, sitagliptin
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 85 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
23
States / cities
Tempe, Arizona • Long Beach, California • Lynwood, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 20, 2026, 3:58 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

DPP-4 Inhibition and TZD for DM Prevention

NCT01006018
View directory record Official record
Conditions
Prediabetic State
Interventions
Sitagliptin + Pioglitazone PLACEBO, Sitagliptin + Pioglitazone, PLACEBO
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 3 Interventional Results available

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

NCT01794143
View directory record Official record
Conditions
Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
Interventions
Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide), Insulin (glargine)
Drug
Lead sponsor
GRADE Study Group
Other
Eligibility
30 Years and older
Enrollment
7,850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient

NCT02182895
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Saxagliptin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 110 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 3 Interventional Results available

Dapagliflozin DPPIV Inhibitor add-on Study

NCT00984867
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
833 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
45
States / cities
Huntsville, Alabama • Ozark, Alabama • Anaheim, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 20, 2026, 3:58 PM EDT
Completed No phase listed Observational

Replication of the LEADER Diabetes Trial in Healthcare Claims

NCT03936049
View directory record Official record
Conditions
Diabetes
Interventions
Liraglutide, DPP-4 inhibitor
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years to 120 Years
Enrollment
168,690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combination Therapy With Sitagliptin and Lansoprazole to Restore Pancreatic Beta Cell Function in Recent-Onset Type 1 Diabetes

NCT01155284
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Sitagliptin and Lansoprazole, Placebo
Drug
Lead sponsor
Sanford Health
Other
Eligibility
11 Years to 45 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
3
States / cities
San Diego, California • Saint Paul, Minnesota • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PKs) of ZYDPLA1 Following Oral Administration in Healthy Volunteers

NCT02620592
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
ZYDPLA1 tablet, Placebo tablet
Drug
Lead sponsor
Zydus Lifesciences Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Not applicable Interventional Results available

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

NCT02130687
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypertension
Interventions
Placebo, Sitagliptin, Aprepitant, Mixed Meal Test (MMT)
Drug · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 20, 2026, 3:58 PM EDT
Withdrawn Phase 3 Interventional

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

NCT02015780
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Fasiglifam, Placebo, Antihyperglycemic therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Whittier, California • Westminster, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Oct 20, 2026, 3:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease

NCT03921242
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
Interventions
Metformin, Sulfonylurea, DPP-4 inhibitor, SGLT2 inhibitor, GLP1 receptor agonist
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
4,888 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 4 Interventional Results available

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

NCT02730377
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, alpha-glucosidase inhibitors, DPP-4 inhibitors, meglitinides, SGLT-2 inhibitors, sulphonylurea, thiazolidinediones
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,991 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
179
States / cities
Birmingham, Alabama • Haleyville, Alabama • Tuscumbia, Alabama + 157 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 20, 2026, 3:58 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus

NCT00690638
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PHX1149T, Placebo
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 85 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
13
States / cities
Norwalk, California • Orange, California • Santa Ana, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2010 · Synced Oct 20, 2026, 3:58 PM EDT